Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

4.40
-0.1700-3.72%
Volume:45.22K
Turnover:199.97K
Market Cap:10.88M
PE:-0.36
High:4.51
Open:4.51
Low:4.33
Close:4.57
52wk High:137.16
52wk Low:2.12
Shares:2.47M
Float Shares:2.02M
Volume Ratio:0.44
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.3857
EPS(LYR):-40.4307
ROE:-503.98%
ROA:-64.67%
PB:0.84
PE(LYR):-0.11

Loading ...

XTL Announces Receipt of Staff Delist Determination from Nasdaq

GlobeNewswire
·
May 23

IMMUNEONCO-B (01541) Achieves Milestone with First Patient Dosed in Phase II SLE Trial for IMM0306

Stock News
·
May 19

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

GlobeNewswire
·
May 19

Complex Warrant Structures May Discourage Strategic Buyers and Limit Shareholder Upside

TIPRANKS
·
May 17

Super League Enterprise Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Super League Q1 FY26 net loss narrows 4% to $4.05 million; revenue rises 10% to $3 million

Reuters
·
May 16

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM

Reuters
·
May 15

Super League Enterprise Q1 Adj. EPS $(0.98) Beats $(2.08) Estimate, Sales $3.003M Beat $2.813M Estimate

Benzinga Earnings
·
May 15

Super League Enterprise Q1 revenue rises, gross margin improves

Reuters
·
May 15

Super League Enterprise Q1 Revenue USD 3 Million

THOMSON REUTERS
·
May 15

Super League Reports First Quarter 2026 Financial Results, Advancing Transition From Corporate Restructuring to Operational Execution

THOMSON REUTERS
·
May 15

Press Release: Super League Reports First Quarter 2026 Financial Results, Advancing Transition from Corporate Restructuring to Operational Execution

Dow Jones
·
May 15

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

GlobeNewswire
·
May 14

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

GlobeNewswire
·
May 14

Super League Enterprise Inc expected to post a loss of $2.08 a share - Earnings Preview

Reuters
·
May 13

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

GlobeNewswire
·
May 13

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 13

Press Release: Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 13

Super League Enterprise director Robert Kalutkiewicz files initial beneficial ownership statement

Reuters
·
May 08

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire
·
May 07